The core activity of Swyssi is the development and manufacture of complex generic drugs, as well as the life cycle extension of established, off-patent medicines, particularly in the areas of cardiology, diabetes, central nervous system and respiratory diseases.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Regulatory approvals for prescription medicines, including rosuvastatin, candesartan combinations, amlodipine combinations, rivaroxaban, antibiotics, sitagliptin/metformin and ticagrelor products.
Complex Generic Drug Products
Complex generic drug products developed and manufactured in GLP- and cGMP-compliant processes, including formulation, characterization, manufacturing and bioequivalence support.
Life-cycle extension of mature prescription pharmaceuticals
Life-cycle extension of divested mature prescription pharmaceuticals, supporting established brands in cardiovascular, diabetes, CNS and respiratory fields.
Pharmacovigilance
Pharmacovigilance for Swyssi products, including safety information, adverse-effect reporting and case handling for patients and healthcare professionals.
Patient Awareness Programs
Patient awareness programs for patients and other audiences, focused on medicines, long-term chronic diseases and health promotion.
Knowledge
No knowledge articles yet
Once Swyssi PMFS AG has claimed this profile, we'll publish editorial articles and case studies here together.